The current von Willebrand disease treatment landscape is classified into three major categories based on the type of drugs used: Non-replacement therapy, Replacement therapy, and Adjunct therapy. Desmopressin is the first line of therapy whereas, replacement therapy is used as a second line of therapy. Some of the FDA-approved VWD replacement therapies include Humate-P (CSL Behring), Alphanate (Octapharma), Wilate (Grifols), Vonvendi (Takeda), and others.